title: [The 12th German Drug Law (AMG) amendment: an obstruction for non-commercial clinical trials?].
authors.affiliation: Zentralinstitut für Seelische Gesundheit, 68167 Mannheim. stefan.schwarz@zi-mannheim.de
authors.forename: S
authors.initials: S
authors.lastname: Schwarz
authors.forename: L
authors.initials: L
authors.lastname: Frölich
authors.forename: J-P
authors.initials: JP
authors.lastname: Striebel
authors.forename: M G
authors.initials: MG
authors.lastname: Hennerici
mesh_terms: D002986:Clinical Trials as Topic / Q000191:economics* / Q000331:legislation & jurisprudence*; D003132:Commerce; D003365:Costs and Cost Analysis; D017277:Drug Approval / Q000191:economics / Q000331:legislation & jurisprudence*; D015507:Drugs, Investigational / Q000627:therapeutic use*; D017041:Ethics Committees; D005380:Financing, Government; D005858:Germany; D019983:Guideline Adherence / Q000331:legislation & jurisprudence; D006801:Humans; D007880:Legislation, Drug; D009313:National Health Programs / Q000191:economics / Q000331:legislation & jurisprudence*; D017410:Practice Guidelines as Topic; D012109:Research Support as Topic
chemical_list: D015507:Drugs, Investigational